Readoutin 13d
Eisai Inc. — Lecanemab IV
Phase 3 primary completion: A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease.
- Date
- Dec 2026
- Type
- Readout
- Indication
- Early Alzheimer's Disease
Readoutin 13d
Phase 3 primary completion: A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease.
The weekly brief is free. Pro adds reminders 7 days and 1 day before.